GlassScriptPhysician profile
Theodore C Friedman
NPI 1972669125
$3,508.22
in general payments reported to CMS, 2019-2025
13 companies · $1,326 in 2025
The $1,326 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,394 · 2020: $48.28 · 2021: $62.11 · 2022: $17.51 · 2023: $253 · 2024: $407 · 2025: $1,326.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $1,185 · Food and Beverage: $758 · Education: $43.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $1,185.00 |
| Food and Beverage | $757.87 |
| Education | $43.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ibsa Pharma INC. | $1,254.43 | 2019-2020 | |
| Acella Pharmaceuticals, LLC | $1,196.00 | 2025 | NP Thyroid 60 |
| Novo Nordisk INC | $443.10 | 2021-2025 | Sogroya, Ozempic, Rybelsus |
| Abbott Laboratories | $223.85 | 2023-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Corcept Therapeutics | $153.50 | 2019-2022 | |
| Dexcom, INC. | $76.25 | 2023-2024 | Dexcom G6 Transmitter |
| Ascend Therapeutics US, LLC | $57.51 | 2020-2021 | |
| Medtronic, INC. | $26.22 | 2025 | Minimed 780g |
| Antares Pharma, INC. | $24.37 | 2019 | |
| Recordati_rare_diseases_inc. | $22.05 | 2023 | Isturisa, Signifor Lar |
| Lilly USA, LLC | $17.51 | 2025 | Mounjaro, Zepbound |
| Avion Pharmaceuticals | $13.43 | 2024 | NP Thyroid 60 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Theodore Friedman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.